Published in Brain on June 09, 2010
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology (2014) 2.45
Quantification of increased cellularity during inflammatory demyelination. Brain (2011) 2.05
Predicting a window of therapeutic opportunity in multiple sclerosis. Brain (2010) 2.03
Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry (2015) 1.63
Will the real multiple sclerosis please stand up? Nat Rev Neurosci (2012) 1.61
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry (2013) 1.60
A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis. Eur J Neurol (2012) 1.51
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol (2014) 1.46
Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis. Brain (2015) 1.40
A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain (2012) 1.22
Age and disability accumulation in multiple sclerosis. Neurology (2011) 1.15
Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain (2013) 1.14
Mindfulness based interventions in multiple sclerosis--a systematic review. BMC Neurol (2014) 1.09
Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol (2011) 1.06
The path to self-management: a qualitative study involving older people with multiple sclerosis. Physiother Can (2012) 1.05
Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol (2012) 1.05
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J (2012) 1.04
Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord (2015) 1.02
An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations. Patient Prefer Adherence (2015) 0.94
Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol (2011) 0.93
Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol (2015) 0.92
Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Dis (2010) 0.92
Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int (2013) 0.90
Optimizing treatment success in multiple sclerosis. J Neurol (2015) 0.90
Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS One (2012) 0.86
Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study. PLoS One (2015) 0.84
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol (2013) 0.84
The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res (2010) 0.84
Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients. PLoS One (2015) 0.83
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler (2014) 0.83
Relapses and disability accumulation in progressive multiple sclerosis. Neurology (2014) 0.83
African ancestry is a predictor factor to secondary progression in clinical course of multiple sclerosis. ISRN Neurol (2012) 0.82
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr (2012) 0.82
Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling tool. PLoS One (2013) 0.82
Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective. Int J MS Care (2012) 0.82
Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US. Clinicoecon Outcomes Res (2013) 0.82
Relation of helicobacter pylori infection and multiple sclerosis in Iranian patients. Neurol Int (2013) 0.81
Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS One (2012) 0.81
Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther (2011) 0.81
Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases. Patient Relat Outcome Meas (2013) 0.81
The impact of slower walking speed on activities of daily living in patients with multiple sclerosis. Int J Clin Pract (2012) 0.81
Induction therapy for patients with multiple sclerosis: why? When? How? CNS Drugs (2013) 0.81
Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Mult Scler (2011) 0.80
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers (2013) 0.80
Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol (2015) 0.80
A mechanistic, stochastic model helps understand multiple sclerosis course and pathogenesis. Int J Genomics (2013) 0.80
Personalized medicine in multiple sclerosis: hope or reality? BMC Med (2012) 0.80
Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. PLoS One (2016) 0.79
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLoS One (2015) 0.79
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurol Ther (2016) 0.79
Temporal lobe cortical pathology and inhibitory GABA interneuron cell loss are associated with seizures in multiple sclerosis. Mult Scler (2015) 0.79
Predictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning. PLoS One (2014) 0.79
The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset. J Neurol (2015) 0.78
Treatment trials in progressive MS--current challenges and future directions. Nat Rev Neurol (2013) 0.77
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults? Mult Scler Int (2011) 0.77
Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. J Neurol (2011) 0.77
Interdisciplinary treatment of patients with multiple sclerosis and chronic pain: a descriptive study. Int J MS Care (2012) 0.77
Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology (2015) 0.76
Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations. Drug Des Devel Ther (2016) 0.75
Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database. Clin Exp Neuroimmunol (2016) 0.75
CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics. J Immunol (2016) 0.75
Environmental factors influencing multiple sclerosis in Latin America. Mult Scler J Exp Transl Clin (2017) 0.75
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients. Sci Rep (2015) 0.75
Outcome Measures in Clinical Trials for Multiple Sclerosis. CNS Drugs (2017) 0.75
Multiple sclerosis: preventing progression and disability in MS-when to treat? Nat Rev Neurol (2013) 0.75
Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study. BMC Health Serv Res (2015) 0.75
Interleukin-17- and interleukin-22-secreting myelin-specific CD4(+) T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients. Immunology (2015) 0.75
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. J Neurol (2015) 0.75
Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clin Transl Immunology (2017) 0.75
Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis. Mult Scler J Exp Transl Clin (2016) 0.75
Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat (2017) 0.75
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon Outcomes Res (2017) 0.75
Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis. Mol Neurobiol (2016) 0.75
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 10.26
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain (1989) 5.59
Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci (2008) 5.15
Relapses and progression of disability in multiple sclerosis. N Engl J Med (2000) 4.17
Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol (2008) 3.92
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain (2003) 3.39
Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain (1980) 3.27
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain (1989) 2.59
A new scale for evaluating disability in multiple sclerosis. Neurology (1955) 2.53
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol (1999) 2.28
Multiple sclerosis in the Japanese population. Lancet Neurol (2003) 2.15
The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain (2006) 1.92
The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain (1999) 1.91
Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology (2001) 1.53
Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet (1991) 1.50
A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop. Neurology (1989) 1.48
The contribution of demyelination to axonal loss in multiple sclerosis. Brain (2006) 1.46
Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology (2000) 1.39
The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain (1999) 1.30
The course of multiple sclerosis in 73 cases with computer-designed curves. Acta Neurol Scand Suppl (1970) 1.29
Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology (1998) 1.27
Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain (1990) 1.25
Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980. Acta Neurol Scand (1982) 1.22
Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler (2003) 1.21
Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada. Neurology (1988) 1.18
The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A (1996) 1.14
The natural history of multiple sclerosis. Can J Neurol Sci (1987) 1.12
Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci (2008) 1.05
Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scand (1981) 0.97
Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler (2001) 0.97
Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol (1989) 0.93
Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet (2003) 4.89
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res (2010) 4.77
Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol (2006) 3.74
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Timing of birth and risk of multiple sclerosis: population based study. BMJ (2004) 2.56
Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet (2008) 2.45
High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ (2012) 2.37
Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet (2005) 2.26
Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet (2009) 2.23
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler (2004) 2.21
Genetics of multiple sclerosis. Lancet Neurol (2004) 2.12
Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol (2011) 2.07
A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet (2005) 2.03
Relapses do not matter in relation to long-term disability: yes. Mult Scler (2011) 2.01
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.69
Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci U S A (2009) 1.69
Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol (2010) 1.64
Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene. Neurology (2012) 1.56
Multiple sclerosis and birth order: a longitudinal cohort study. Lancet Neurol (2005) 1.54
The inheritance of resistance alleles in multiple sclerosis. PLoS Genet (2007) 1.54
T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest (2014) 1.53
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr (2008) 1.49
Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans. Genome Res (2012) 1.45
Month of birth, vitamin D and risk of immune-mediated disease: a case control study. BMC Med (2012) 1.44
Microarray-based classification and clinical predictors: on combined classifiers and additional predictive value. Bioinformatics (2008) 1.39
Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med (2009) 1.31
Anorectal malignant melanoma: extensive 45-year review and proposal for a novel staging classification. J Am Coll Surg (2013) 1.29
Genomewide study of multiple sclerosis. N Engl J Med (2007) 1.28
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain (2012) 1.27
Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol (2009) 1.27
Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurol (2009) 1.19
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol (2006) 1.17
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. Hum Mol Genet (2009) 1.17
Mortality in patients with multiple sclerosis. Neurology (2013) 1.15
HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci U S A (2008) 1.11
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry (2011) 1.09
Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium. Hum Mol Genet (2007) 1.08
Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis. J Hum Genet (2009) 1.08
Genetic epidemiology: the use of old and new tools for multiple sclerosis. Trends Neurosci (2008) 1.07
Association between walking speed and age in healthy, free-living individuals using mobile accelerometry--a cross-sectional study. PLoS One (2011) 1.06
The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer - a Comprehensive review. J Cancer (2013) 1.05
Genetic, environmental and stochastic factors in monozygotic twin discordance with a focus on epigenetic differences. BMC Med (2012) 1.04
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
A genome-wide scan in forty large pedigrees with multiple sclerosis. J Hum Genet (2007) 1.02
Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology (2009) 1.02
Maternal transmission of multiple sclerosis in a dutch population. Arch Neurol (2008) 1.01
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open (2012) 1.00
Anti-tumor necrosis factor alpha-associated multiple sclerosis. AJNR Am J Neuroradiol (2005) 0.97
Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease. BMC Med (2013) 0.97
Significant linkage to migraine with aura on chromosome 11q24. Hum Mol Genet (2003) 0.96
An extended genome scan in 442 Canadian multiple sclerosis-affected sibships: a report from the Canadian Collaborative Study Group. Hum Mol Genet (2004) 0.96
Type 1 diabetes mellitus and multiple sclerosis: common etiological features. Nat Rev Endocrinol (2009) 0.95
PRKCA and multiple sclerosis: association in two independent populations. PLoS Genet (2006) 0.95
Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant (2012) 0.94
Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J Cancer (2013) 0.93
Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: a descriptive study. J Neurol Neurosurg Psychiatry (2011) 0.93
Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog (2005) 0.92
Multiple sclerosis: major histocompatibility complexity and antigen presentation. Genome Med (2009) 0.92
The epidemiology of multiple sclerosis in Scotland: inferences from hospital admissions. PLoS One (2011) 0.92
Accuracy of the actibelt(®) accelerometer for measuring walking speed in a controlled environment among persons with multiple sclerosis. Gait Posture (2011) 0.92
High-resolution anatomic, diffusion tensor, and magnetization transfer magnetic resonance imaging of the optic chiasm at 3T. J Magn Reson Imaging (2005) 0.91
Development and validation of a new method to measure walking speed in free-living environments using the actibelt® platform. PLoS One (2011) 0.91
Parental transmission of HLA-DRB1*15 in multiple sclerosis. Hum Genet (2007) 0.91
Genes for multiple sclerosis. Lancet (2008) 0.91
The genetics of clinical outcome in multiple sclerosis. J Neuroimmunol (2008) 0.90
Functional analysis of missense variants in the TRESK (KCNK18) K channel. Sci Rep (2012) 0.90
A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis. Sci Transl Med (2009) 0.90
An extension to a statistical approach for family based association studies provides insights into genetic risk factors for multiple sclerosis in the HLA-DRB1 gene. BMC Med Genet (2009) 0.90
Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol (2007) 0.89
Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology (2010) 0.88
Parent-of-origin effects at the major histocompatibility complex in multiple sclerosis. Hum Mol Genet (2010) 0.88
Vitamin D receptor binding, chromatin states and association with multiple sclerosis. Hum Mol Genet (2012) 0.88
Association of smoking with risk of multiple sclerosis: a population-based study. J Neurol (2013) 0.87
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC). Discov Med (2011) 0.87
Autologous hematopoietic stem cell transplantation for autoimmune disease--is it now ready for prime time? Biol Blood Marrow Transplant (2012) 0.87
Competing interests in multiple sclerosis research. Lancet (2003) 0.87
What is the "normal" fetal heart rate? PeerJ (2013) 0.86
Progress in deciphering the genetics of multiple sclerosis. Curr Opin Neurol (2003) 0.85
Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol (2013) 0.85
Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J Immunol (2006) 0.85
Prognosis of the individual course of disease: the elements of time, heterogeneity and precision. J Neurol Sci (2009) 0.85
Hand preference and performance in 20 pairs of monozygotic twins with discordant handedness. Cortex (2006) 0.84
Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J Neurol Sci (2011) 0.84
Seasonal distribution of psychiatric births in England. PLoS One (2012) 0.83
Association between microchimerism and multiple sclerosis in Canadian twins. J Neuroimmunol (2006) 0.83
Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice. J Exp Med (2004) 0.83
Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling tool. PLoS One (2013) 0.82
Immune re-education following autologous hematopoietic stem cell transplantation. Autoimmunity (2008) 0.82
Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. J Cancer (2013) 0.82
A genome-wide scan of male sexual orientation. J Hum Genet (2010) 0.82
Inactive or moderately active human promoters are enriched for inter-individual epialleles. Genome Biol (2013) 0.82